Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative, and skeletal muscle relaxant properties. It acts as a central nervous system depressant and is primarily indicated for the treatment of anxiety disorders. Oxazolam functions as a prodrug for desmethyldiazepam (also known as nordazepam), which means it is metabolized in the body to its active form. The drug exerts its effects by enhancing the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors in the brain, leading to increased chloride ion influx and hyperpolarization of neuronal membranes. This results in inhibition of nerve signal transmission and produces calming effects. Oxazolam may also be used off-label for insomnia or as a pre-anesthetic medication[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxazolam.